Revumenib (SNDX-5613) is a potent and selective inhibitor of menin-MLL binding with Ki of 0.149 nM.
SNDX5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.
Treatment with SNDX-5613 and venetoclax reduced leukemia burden and significantly improved survival of NSG mice bearing MLL1-r or mtNPM1 with mtFLT3 AML xenografts.
